U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H14N2
Molecular Weight 186.253
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALTINICLINE

SMILES

CN1CCC[C@H]1C2=CN=CC(=C2)C#C

InChI

InChIKey=NUPUDYKEEJNZRG-LBPRGKRZSA-N
InChI=1S/C12H14N2/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2/h1,7-9,12H,4-6H2,2H3/t12-/m0/s1

HIDE SMILES / InChI
Molecular Formula C12H14N2
Molecular Weight 186.253
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/10812948 https://www.ncbi.nlm.nih.gov/pubmed/18692487

Altinicline (SIB-1508Y, SIB-1765F) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype. It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models, and progressed as far as Phase II clinical trials for Parkinson's disease, where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.

CNS Activity

CNS Penetrant
2588

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 7.5 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
40 mg 2 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
Other AEs: Nausea and vomiting...
Other AEs:
Nausea and vomiting
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
10 mg 2 times / day multiple, oral
MTD
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
Other AEs: Lightheadedness, Dizziness...
Other AEs:
Lightheadedness
Dizziness
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
20 mg 2 times / day multiple, oral
Studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
Disc. AE: Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (serious, 1 pt)
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
AEs

AEs

AESignificanceDosePopulation
Nausea and vomiting
40 mg 2 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
Dizziness
10 mg 2 times / day multiple, oral
MTD
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
Lightheadedness
10 mg 2 times / day multiple, oral
MTD
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
Thrombocytopenia serious, 1 pt
Disc. AE
20 mg 2 times / day multiple, oral
Studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16476941
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P0027A2
https://www.1pchem.com/search?query=1P0027A2
Alfa Chemistry
179120-92-4
http://www.alfa-chemistry.com/search.aspx?q=179120-92-4
Alfa Chemistry
ACM179120924
http://www.alfa-chemistry.com/search.aspx?q=ACM179120924
Chemspace
CSC009867726
https://chem-space.com/CSC009867726
Chemspace
CSC015398323
https://chem-space.com/CSC015398323
Compound Cloud
11954277
Compound Cloud
3036156
eMolecules
295589291
https://orderbb.emolecules.com/search/#?query=295589291
eMolecules
31592689
https://orderbb.emolecules.com/search/#?query=31592689
Enamine
BBV-38269655
http://www.enaminestore.com/catalog/BBV-38269655
Enamine
BBV-39756269
http://www.enaminestore.com/catalog/BBV-39756269
MolPort
MolPort-035-765-828
https://www.molport.com/shop/molecule-link/MolPort-035-765-828
MuseChem
I011022
https://www.musechem.com/product/I011022.html
MuseChem
R008808
https://www.musechem.com/product/R008808.html
Tocris
4766
https://www.tocris.com/search.php?Type=QuickSearch&Value=4766
Wonderchem
WD05FUC
http://www.wonder-chem.com/search.html?text=WD05FUC
PubMed

PubMed

TitleDatePubMed
Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine.
2000-09
Patents

Patents

US2010267739
2
US8030300
2

Sample Use Guides

In Vivo Use Guide
10 mg daily
Route of Administration: Oral
In Vitro Use Guide
[3H]-DA uptake in rat striatal synaptosomes was conducted as described before: briefly, 100 μl of crude P2 synaptosomal fraction were preincubated in the presence of varying concentrations of test compounds (SIB-1765F) for 10 min before the addition of [3H]-DA final concentration of 10 nM
Substance Class Chemical
Created
by admin
on Wed Apr 02 08:24:06 GMT 2025
Edited
by admin
on Wed Apr 02 08:24:06 GMT 2025
Record UNII
RJ9V9V09VM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALTINICLINE
INN  
INN  
Official Name English
(-)-5-ETHYNYLNICOTINE
Preferred Name English
(S)-3-ETHYNYL-5-(1-METHYL-2-PYRROLIDINYL)PYRIDINE
Systematic Name English
altinicline [INN]
Common Name English
(-)-3-ETHYNYL-5-((S)-1-METHYL-2-PYRROLIDINYL)PYRIDINE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C73579
Created by admin on Wed Apr 02 08:24:06 GMT 2025 , Edited by admin on Wed Apr 02 08:24:06 GMT 2025
Code System Code Type Description
INN
7916
Created by admin on Wed Apr 02 08:24:06 GMT 2025 , Edited by admin on Wed Apr 02 08:24:06 GMT 2025
PRIMARY
CAS
179120-92-4
Created by admin on Wed Apr 02 08:24:06 GMT 2025 , Edited by admin on Wed Apr 02 08:24:06 GMT 2025
PRIMARY
WIKIPEDIA
ALTINICLINE
Created by admin on Wed Apr 02 08:24:06 GMT 2025 , Edited by admin on Wed Apr 02 08:24:06 GMT 2025
PRIMARY
EPA CompTox
DTXSID40870143
Created by admin on Wed Apr 02 08:24:06 GMT 2025 , Edited by admin on Wed Apr 02 08:24:06 GMT 2025
PRIMARY
ChEMBL
CHEMBL111659
Created by admin on Wed Apr 02 08:24:06 GMT 2025 , Edited by admin on Wed Apr 02 08:24:06 GMT 2025
PRIMARY
PUBCHEM
3036156
Created by admin on Wed Apr 02 08:24:06 GMT 2025 , Edited by admin on Wed Apr 02 08:24:06 GMT 2025
PRIMARY
NCI_THESAURUS
C77841
Created by admin on Wed Apr 02 08:24:06 GMT 2025 , Edited by admin on Wed Apr 02 08:24:06 GMT 2025
PRIMARY
SMS_ID
300000037027
Created by admin on Wed Apr 02 08:24:06 GMT 2025 , Edited by admin on Wed Apr 02 08:24:06 GMT 2025
PRIMARY
FDA UNII
RJ9V9V09VM
Created by admin on Wed Apr 02 08:24:06 GMT 2025 , Edited by admin on Wed Apr 02 08:24:06 GMT 2025
PRIMARY
Related Record Type Details
Structure of ALTINICLINE MALEATE
SALT/SOLVATE -> PARENT
?4?2 Nicotinic acetylcholine receptor
TARGET -> AGONIST
Related Record Type Details
Structure of ALTINICLINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966